全文获取类型
收费全文 | 88741篇 |
免费 | 6664篇 |
国内免费 | 267篇 |
专业分类
耳鼻咽喉 | 1112篇 |
儿科学 | 2303篇 |
妇产科学 | 1389篇 |
基础医学 | 11920篇 |
口腔科学 | 1020篇 |
临床医学 | 9500篇 |
内科学 | 19202篇 |
皮肤病学 | 957篇 |
神经病学 | 8574篇 |
特种医学 | 3457篇 |
外科学 | 13926篇 |
综合类 | 1011篇 |
一般理论 | 99篇 |
预防医学 | 6651篇 |
眼科学 | 2129篇 |
药学 | 6075篇 |
中国医学 | 97篇 |
肿瘤学 | 6250篇 |
出版年
2023年 | 630篇 |
2022年 | 1062篇 |
2021年 | 2497篇 |
2020年 | 1413篇 |
2019年 | 2296篇 |
2018年 | 2659篇 |
2017年 | 1901篇 |
2016年 | 2004篇 |
2015年 | 2327篇 |
2014年 | 3407篇 |
2013年 | 4307篇 |
2012年 | 6894篇 |
2011年 | 7156篇 |
2010年 | 3906篇 |
2009年 | 3412篇 |
2008年 | 5743篇 |
2007年 | 5961篇 |
2006年 | 5565篇 |
2005年 | 5510篇 |
2004年 | 5065篇 |
2003年 | 4616篇 |
2002年 | 4220篇 |
2001年 | 955篇 |
2000年 | 732篇 |
1999年 | 880篇 |
1998年 | 905篇 |
1997年 | 681篇 |
1996年 | 594篇 |
1995年 | 545篇 |
1994年 | 501篇 |
1993年 | 490篇 |
1992年 | 586篇 |
1991年 | 505篇 |
1990年 | 441篇 |
1989年 | 436篇 |
1988年 | 357篇 |
1987年 | 350篇 |
1986年 | 332篇 |
1985年 | 323篇 |
1984年 | 318篇 |
1983年 | 277篇 |
1982年 | 327篇 |
1981年 | 294篇 |
1980年 | 243篇 |
1979年 | 228篇 |
1978年 | 208篇 |
1977年 | 161篇 |
1976年 | 122篇 |
1975年 | 128篇 |
1974年 | 142篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
4.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
5.
Timo Rath Lukas Pfeifer Clemens Neufert reas Kremer Moritz Leppkes Arthur Hoffman Markus F Neurath Steffen Zopf 《World journal of gastroenterology : WJG》2020,26(16):1962-1970
BACKGROUND The adenoma detection rate(ADR) is inversely associated with the incidence of interval colorectal cancer and serves as a benchmark quality criterion during screening colonoscopy. However, adenoma miss rates reach up to 26% and studies have shown that a second inspection of the right colon in retroflected view(RFV) can increase ADR.AIM To assess whether inspection of the whole colon in RFV compared to standard forward view(SFV) can increase ADR.METHODS Patients presenting for screening or surveillance colonoscopy were invited to participate in this randomized controlled trial and randomized into two arms. In RFV arm colonoscopy was initially performed with SFV, followed by a second inspection of the whole colon in RFV. In the SFV arm first withdrawal was performed with SFV, followed by a second inspection of the whole colon again with SFV. Number, size and morphology of polyps found during first and second inspection in each colonic segment were recorded and all polyps were removed and sent for histopathology in separate containers.RESULTS Two hundred and five patients were randomly assigned to the RFV(n = 101) and SFV(n = 104) arm. In the RFV arm, both polyp detection rate(PDR) and ADR were increased under second inspection in RFV(PDR 1~(st) SFV: 39.8%, PDR 2~(nd)RFV: 46.6%; ADR 1~(st) SFV: 35.2%, ADR 2~(nd) RFV: 42%). Likewise, in the SFV arm,PDR and ADR were increased under second inspection(PDR 1~(st) SFV: 37.5%, PDR 2~(nd) SFV: 46.6%; ADR 1~(st) SFV: 34.1%, ADR 2~(nd)SFV: 44.3%) with no significant differences in ADR and PDR between the SFV and RFV arm. Mean number of adenomas per patient(APP) was increased in the RFV and SFV(APP RFV arm: 1~(st) SFV: 1.71; 2~(nd) RFV: 2.38; APP SFV arm: 1~(st) SFV: 1.83, 2~(nd)SFV:2.2). The majority of adenomas additionally found during second inspection in RFV or in SFV were located in the transverse and left-sided colon and were 5 mm in size.CONCLUSION Second inspection of the whole colon leads to increased adenoma detection with no differences between SFV and RFV. Hence, increased detection is most likely a feature of the second inspection itself but not of the inspection mode. 相似文献
6.
7.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献8.
9.
10.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献